Pieris Pharmaceuticals, Inc. (PIRS): Louis Matis , SVP, Chief Development Officer of Pieris Pharmaceuticals, Inc. purchased 10,000 shares on Jun 13, 2016. The Insider buying transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.70 per share for a total value of $17,037.45 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 8, 2015, Chau Quang Khuong (director 10% owner) purchased 500,000 shares at $2.75 per share price.
Pieris Pharmaceuticals Inc: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in Pieris Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $1.67 and hit $1.71 on the upside , eventually ending the session at $1.7, with a gain of 3.66% or 0.06 points. The heightened volatility saw the trading volume jump to 52,803 shares. The 52-week high of the share price is $4.4 and the company has a market cap of $68 M . The 52-week low of the share price is at $1.26.
Pieris Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of Anticalin class of biotherapeutics for patients with diseases. The Company is focused on developing two drug candidates PRS-080 and PRS-060. PRS-080 is an Anticalin protein that binds to hepcidin a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency (FID) in anemic patients with chronic kidney disease (CKD) in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor thereby inhibiting IL-4 and IL-13 two cytokines small proteins mediating signaling between cells within the human body which are mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. It is also developing PRS-110 in cMet-related cancer and PRS-300 series.